Observation of Treatment Patterns With Lucentis in Approved Indications

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5778 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-08

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

NCT04847895

Neovascular (Wet) Age-related Macular Degeneration

COMPLETED

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

NCT01269151

COMPLETED NA

Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

NCT01638858

Age-Related Macular Degeneration

COMPLETED NA

Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD

NCT00574093

Neovascular Age Related Macular Degeneration

COMPLETED PHASE2

Study EvAluating Genotypes While Using Lucentis 2

NCT01464723

Age-Related Macular Degeneration

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort with routine OCT monitoring

No interventions assigned to this group

Cohort without routine OCT monitoring

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of

* neovascular (wet) age-related macular degeneration (AMD),
* visual impairment due to diabetic macular oedema (DME),
* visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) or
* visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
* Patients for whom a therapy with Lucentis® is medically indicated.
* Written patients informed consent.

Exclusion Criteria

* As described in the SmPC.
* Preceding intravitreal treatment of the study eye with anti-VEGF drugs in the last three months before enrollment
* Preceding intravitreal treatment of the study eye with steroids

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No